From white bullets to black markets and greened medicine

The neuroeconomics and neuroracial politics of opioid pharmaceuticals

Helena Hansen, Mary E. Skinner

    Research output: Contribution to journalArticle

    Abstract

    Synthetic opiates (opioids) have created among the most profitable markets worldwide. Two decades ago, FDA approval of Oxycontin® as a "minimally addictive" opioid pain reliever fueled an unprecedented rise in prescription opioid abuse. This was followed by a little known act of U.S. Congress enabling general physicians to use an opioid maintenance medication, buprenorphine, for addiction treatment in their private practices, leading to enormous growth in the U.S. addiction treatment market. Based on participant-observation and interviews among pharmaceutical executives, policy makers, patients and prescribers, this article describes the neuroeconomics and neuropolitics of new opioid maintenance treatments. This article contrasts the historical emergence of methadone clinics from the 1960s to the 1980s as a treatment for the Black and Latino urban poor, with the current emergence of buprenorphine, a maintenance opioid approved for prescription on doctor's offices, as a treatment for white, middle-class prescription opioid abusers. The article then traces the counterintuitive result of bringing addiction pharmaceuticals into the medical mainstream in an effort to reduce the stigma of addiction: a two tiered system of addiction treatment that reinforces stigma among the urban poor, and enhances the biological, political, and economic dependence of all classes on opioid markets, both legal and illegal.

    Original languageEnglish (US)
    Pages (from-to)167-182
    Number of pages16
    JournalAnnals of Anthropological Practice
    Volume36
    Issue number1
    DOIs
    StatePublished - May 2012

    Fingerprint

    black market
    addiction
    pharmaceutical
    medicine
    medication
    politics
    market
    economic dependence
    political independence
    participant observation
    middle class
    pain
    abuse
    physician
    interview

    Keywords

    • Addiction treatment
    • Buprenorphine
    • Class
    • Methadone
    • Opiate maintenance
    • Pharmaceuticals
    • Political economy
    • Race

    ASJC Scopus subject areas

    • Anthropology

    Cite this

    From white bullets to black markets and greened medicine : The neuroeconomics and neuroracial politics of opioid pharmaceuticals. / Hansen, Helena; Skinner, Mary E.

    In: Annals of Anthropological Practice, Vol. 36, No. 1, 05.2012, p. 167-182.

    Research output: Contribution to journalArticle

    @article{d08c2841ebe54505b1890404c31df5b4,
    title = "From white bullets to black markets and greened medicine: The neuroeconomics and neuroracial politics of opioid pharmaceuticals",
    abstract = "Synthetic opiates (opioids) have created among the most profitable markets worldwide. Two decades ago, FDA approval of Oxycontin{\circledR} as a {"}minimally addictive{"} opioid pain reliever fueled an unprecedented rise in prescription opioid abuse. This was followed by a little known act of U.S. Congress enabling general physicians to use an opioid maintenance medication, buprenorphine, for addiction treatment in their private practices, leading to enormous growth in the U.S. addiction treatment market. Based on participant-observation and interviews among pharmaceutical executives, policy makers, patients and prescribers, this article describes the neuroeconomics and neuropolitics of new opioid maintenance treatments. This article contrasts the historical emergence of methadone clinics from the 1960s to the 1980s as a treatment for the Black and Latino urban poor, with the current emergence of buprenorphine, a maintenance opioid approved for prescription on doctor's offices, as a treatment for white, middle-class prescription opioid abusers. The article then traces the counterintuitive result of bringing addiction pharmaceuticals into the medical mainstream in an effort to reduce the stigma of addiction: a two tiered system of addiction treatment that reinforces stigma among the urban poor, and enhances the biological, political, and economic dependence of all classes on opioid markets, both legal and illegal.",
    keywords = "Addiction treatment, Buprenorphine, Class, Methadone, Opiate maintenance, Pharmaceuticals, Political economy, Race",
    author = "Helena Hansen and Skinner, {Mary E.}",
    year = "2012",
    month = "5",
    doi = "10.1111/j.2153-9588.2012.01098.x",
    language = "English (US)",
    volume = "36",
    pages = "167--182",
    journal = "Annals of Anthropological Practice",
    issn = "2153-957X",
    publisher = "John Wiley and Sons Ltd",
    number = "1",

    }

    TY - JOUR

    T1 - From white bullets to black markets and greened medicine

    T2 - The neuroeconomics and neuroracial politics of opioid pharmaceuticals

    AU - Hansen, Helena

    AU - Skinner, Mary E.

    PY - 2012/5

    Y1 - 2012/5

    N2 - Synthetic opiates (opioids) have created among the most profitable markets worldwide. Two decades ago, FDA approval of Oxycontin® as a "minimally addictive" opioid pain reliever fueled an unprecedented rise in prescription opioid abuse. This was followed by a little known act of U.S. Congress enabling general physicians to use an opioid maintenance medication, buprenorphine, for addiction treatment in their private practices, leading to enormous growth in the U.S. addiction treatment market. Based on participant-observation and interviews among pharmaceutical executives, policy makers, patients and prescribers, this article describes the neuroeconomics and neuropolitics of new opioid maintenance treatments. This article contrasts the historical emergence of methadone clinics from the 1960s to the 1980s as a treatment for the Black and Latino urban poor, with the current emergence of buprenorphine, a maintenance opioid approved for prescription on doctor's offices, as a treatment for white, middle-class prescription opioid abusers. The article then traces the counterintuitive result of bringing addiction pharmaceuticals into the medical mainstream in an effort to reduce the stigma of addiction: a two tiered system of addiction treatment that reinforces stigma among the urban poor, and enhances the biological, political, and economic dependence of all classes on opioid markets, both legal and illegal.

    AB - Synthetic opiates (opioids) have created among the most profitable markets worldwide. Two decades ago, FDA approval of Oxycontin® as a "minimally addictive" opioid pain reliever fueled an unprecedented rise in prescription opioid abuse. This was followed by a little known act of U.S. Congress enabling general physicians to use an opioid maintenance medication, buprenorphine, for addiction treatment in their private practices, leading to enormous growth in the U.S. addiction treatment market. Based on participant-observation and interviews among pharmaceutical executives, policy makers, patients and prescribers, this article describes the neuroeconomics and neuropolitics of new opioid maintenance treatments. This article contrasts the historical emergence of methadone clinics from the 1960s to the 1980s as a treatment for the Black and Latino urban poor, with the current emergence of buprenorphine, a maintenance opioid approved for prescription on doctor's offices, as a treatment for white, middle-class prescription opioid abusers. The article then traces the counterintuitive result of bringing addiction pharmaceuticals into the medical mainstream in an effort to reduce the stigma of addiction: a two tiered system of addiction treatment that reinforces stigma among the urban poor, and enhances the biological, political, and economic dependence of all classes on opioid markets, both legal and illegal.

    KW - Addiction treatment

    KW - Buprenorphine

    KW - Class

    KW - Methadone

    KW - Opiate maintenance

    KW - Pharmaceuticals

    KW - Political economy

    KW - Race

    UR - http://www.scopus.com/inward/record.url?scp=84866563760&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84866563760&partnerID=8YFLogxK

    U2 - 10.1111/j.2153-9588.2012.01098.x

    DO - 10.1111/j.2153-9588.2012.01098.x

    M3 - Article

    VL - 36

    SP - 167

    EP - 182

    JO - Annals of Anthropological Practice

    JF - Annals of Anthropological Practice

    SN - 2153-957X

    IS - 1

    ER -